FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL 3235-0287 Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person*     Ali Faraz						2. Issuer Name and Ticker or Trading Symbol Tenaya Therapeutics, Inc. [TNYA]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
An Faraz														1	Direc	tor		10% O\	vner
(Last) (First) (Middle)				3. Date of Earliest Transaction (Month/Day/Year) 08/16/2024									<b>√</b>	belov	,		Other (s	specify	
C/O TENAYA THERAPEUTICS, INC.															Chief Executive Officer				
171 OYSTER POINT BLVD., 5TH FLOOR						4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line)					
(Street)														1	Form filed by One Reporting Person				on
SOUTH SAN FRANCISCO CA 94080													Form Perso	rm filed by More than One Reporting rson					
FRANCISCO					Rule 10b5-1(c) Transaction Indication														
(City) (State) (7ip)						Trais 1000 1(0) Traisaction maleation													
(City)	City) (State) (Zip)									nsaction was m tions of Rule 1					uction or writt	en pla	an that is inter	nded to	
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																			
1. Title of Security (Instr. 3)  2. Transactic Date (Month/Day/				rear) i	if any	ion Date,		Transaction Code (Instr. 8)		4. Securities Disposed Of	ocurities Acquired (A) ocurities Acquired (A) ocurities Acquired (A) ocuries (		d 5) Securi Benefi Owned		ities Folicially (D following (I)		m: Direct or Indirect nstr. 4)	7. Nature of Indirect Beneficial Ownership	
									Code	v	Amount	(A) or (D)	Price			ted action(s) 3 and 4)	on(s)		(Instr. 4)
Common Stock 08/16/202					24				<b>S</b> <sup>(1)</sup>		5,802	D	\$2.894	5(2)	192	192,277(3)		D	
Common Stock 08/16/20					24				S <sup>(4)</sup>		3,946	D	\$2.894	188,331 <sup>(</sup>		3,331(3)	3) D		
		Tal	ble II	- Derivati											Owne	d			
				(e.g., pu	its, ca	alis, v	varra	ınts	, opti	ons,	convertib	le se	curities	)					
1. Title of Derivative Security (Instr. 3)	ative Conversion Date Execution Date, rity or Exercise (Month/Day/Year) if any			4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable an Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Inst 3 and 4)		8. Price of Derivative Security (Instr. 5)		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exer	cisable	Expiration Date	Title	Amount or Number of Shares						

## **Explanation of Responses:**

- 1. Shares sold to cover tax withholding obligations in connection with the vesting of restricted stock units awarded on February 15, 2023.
- 2. Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from \$2.79 to \$3.02. Reporting Person undertakes to provide Tenaya Therapeutics, Inc., any security holder of Tenaya Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- 3. Includes 152,500 shares of Tenaya Therapeutics, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.
- 4. Shares sold to cover tax withholding obligations in connection with the vesting of restricted stock units awarded on February 23, 2024.

/s/ Jennifer Drimmer

08/16/2024

Rokovich, Attorney-in-Fact \*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.